Salveen Richter, an analyst from Goldman Sachs, maintained the Buy rating on Biogen. The associated price target remains the same with $231.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Salveen Richter has given his Buy rating due to a combination of factors related to Biogen’s evolving product mix and disciplined capital allocation. She highlights management’s strategy to offset pressure in the legacy MS franchise by channeling resources into higher-growth assets, including the Spinraza lifecycle, next-generation salanersen, and a focused late-stage pipeline, while holding overall operating expenses roughly flat.
Richter also emphasizes the upside from business development capacity, potential value creation from Phase 3 programs like litifilimab and felzartamab, and the growing contribution from newer launches such as Leqembi, Skyclarys, Qalsody, and Zurzuvae. Together with a completed cost-savings program and a 2025–2027 setup that she views as supportive of margin stability and revenue acceleration, these elements underpin her expectation that 2027 can be a strong year and justify a positive stance on the shares.
In another report released on March 12, Oppenheimer also maintained a Buy rating on the stock with a $250.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year.